Variants on ESR1 and their association with prostate cancer risk: A meta-analysis

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 8, 2012, Pages 3931-3936

  Ding, Xiang ^a   Cui, Feng Mei ^b,c   Xu, Song Tao ^d   Pu, Jin Xian ^a   Huang, Yu Hua ^a   Zhang, Jiang Lei ^a   Wei, Xue Dong ^a   Hou, Jian Quan ^a   Yan, Chun Yin ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b School of Radiation Medicine and Public Health   (China)

^c MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^d Soochow Medical College of Soochow University   (China)

Author keywords

Esr1; Meta analysis; Polymorphisms; Prostate cancer

Indexed keywords

EID: 84873669133     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.8.3931     Document Type: Article

References (36)

1. Ashton KA, Proietto A, Otton G, et al (2009). Estrogen receptor polymorphisms and the risk of endometrial cancer. BJOG, 116, 1053-61.
2. Begg CB & Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-101.
3. Berndt SI, Chatterjee N, Huang WY, et al (2007). Variant in sex hormone-binding globulin gene and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev, 16, 165-8.
4. Beuten J, Gelfond JA, Franke JL, et al (2009). Single and multigenic analysis of the association between variants in 12 steroid hormone metabolism genes and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev, 18, 1869-80.
5. Celhay O, Yacoub M, Irani J, et al (2010). Expression of estrogen related proteins in hormone refractory prostate cancer: association with tumor progression. J Urol, 184, 2172-8.
6. Cunningham JM, Hebbring SJ, McDonnell SK, et al (2007). Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Cancer Epidemiol Biomarkers Prev 16, 969-78.
7. Doherty JA, Rossing MA, Cushing-Haugen KL, et al (2010). ESR1/SYNE1 polymorphism and invasive epithelial ovarian cancer risk: an Ovarian Cancer Association Consortium study. Cancer Epidemiol Biomarkers Prev, 19, 245-50.
8. Einarsdottir K, Darabi H, Czene K, et al (2009) Common genetic variability in ESR1 and EGF in relation to endometrial cancer risk and survival. Br J Cancer, 100, 1358-64.
9. Fukatsu T, Hirokawa Y, Araki T, et al (2004). Genetic polymorphisms of hormone-related genes and prostate cancer risk in the Japanese population. Anticancer Res 24, 2431-7.
10. Goulart AC, Zee RY, Rexrode KM (2009). Estrogen receptor 1 gene polymorphisms and decreased risk of obesity in women. Metabolism, 58, 759-64.
11. Gupta L, Thakur H, Sobti RC, et al (2010). Role of genetic polymorphism of estrogen receptor-alpha gene and risk of prostate cancer in north Indian population. Mol Cell Biochem 335, 255-61.
12. Harkonen PL, Makela SI (2004). Role of estrogens in development of prostate cancer. J Steroid Biochem Mol Biol, 92, 297-305.
13. Hernandez J, Balic I, Johnson-Pais TL, et al (2006). Association between an estrogen receptor alpha gene polymorphism and the risk of prostate cancer in black men. J Urol, 175, 523-7.
14. Hsing AW, Chokkalingam AP (2006). Prostate cancer epidemiology. Front Biosci, 11, 1388-413.
15. Ioannidis JP, Ralston SH, Bennett ST, et al (2004) Differential genetic effects of ESR1 gene polymorphisms on osteoporosis outcomes. JAMA, 292, 2105-14.
16. Iwasaki M, Tsugane S (2005). [Risk factors and current chemoprevention studies in prostate cancer]. Nihon Rinsho, 63, 321-6.
17. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
18. Kjaergaard AD, Ellervik C, Tybjaerg-Hansen A, et al (2007). Estrogen receptor alpha polymorphism and risk of cardiovascular disease, cancer, and hip fracture: crosssectional, cohort, and case-control studies and a metaanalysis. Circulation, 115, 861-71.
19. Li N, Dong J, Hu Z, et al (2010). Potentially functional polymorphisms in ESR1 and breast cancer risk: a metaanalysis. Breast Cancer Res Treat, 121, 177-84.
20. Low YL, Taylor JI, Grace PB, et al (2006). Phytoestrogen exposure, polymorphisms in COMT, CYP19, ESR1, and SHBG genes, and their associations with prostate cancer risk. Nutr Cancer, 56, 31-9.
21. Modugno F, Weissfeld JL, Trump DL, et al (2001). Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk. Clin Cancer Res, 7, 3092-6.
22. Muthusamy S, Andersson S, Kim HJ, et al (2011). Estrogen receptor beta and 17beta-hydroxysteroid dehydrogenase type 6, a growth regulatory pathway that is lost in prostate cancer. Proc Natl Acad Sci USA, 108, 20090-4.
23. Nelles JL, Hu WY, Prins GS (2011). Estrogen action and prostate cancer. Expert Rev Endocrinol Metab 6, 437-51.
24. Onsory K, Sobti RC, Al-Badran AI, et al (2008). Hormone receptor-related gene polymorphisms and prostate cancer risk in North Indian population. Mol Cell Biochem, 314, 25-35.
25. Peters JL, Sutton AJ, Jones DR, et al (2007). Performance of the trim and fill method in the presence of publication bias and between-study heterogeneity. Stat Med, 26, 4544-62.
26. S-Cunningham JM, Hebbring SJ, McDonnell SK, et al (2007). Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Cancer Epidemiol Biomarkers Prev, 16, 969-78.
27. Safarinejad MR, Safarinejad S, Shafiei N (2012). Estrogen receptors alpha (rs2234693 and rs9340799), and beta (rs4986938 and rs1256049) genes polymorphism in prostate cancer: Evidence for association with risk and histopathological tumor characteristics in Iranian men. Mol Carcinog.
28. Safarinejad MR, Shafiei N, Safarinejad S (2010). Association of polymorphisms in the estrogen receptors alpha, and beta (ESR1, ESR2) with the occurrence of male infertility and semen parameters. J Steroid Biochem Mol Biol, 122, 193-203.
29. Sissung TM, Danesi R, Kirkland CT, et al (2011). Estrogen receptor alpha and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castrationresistant prostate cancer treated with docetaxel-based therapy. J Clin Endocrinol Metab, 96, E368-72.
30. Sobti RC, Gupta L, Singh SK, et al (2008). Role of hormonal genes and risk of prostate cancer: gene-gene interactions in a North Indian population. Cancer Genet Cytogenet, 185, 78-85.
31. Sonoda T, Suzuki H, Mori M, et al (2010). Polymorphisms in estrogen related genes may modify the protective effect of isoflavones against prostate cancer risk in Japanese men. Eur J Cancer Prev, 19, 131-7.
32. Suzuki K, Nakazato H, Matsui H, et al (2003). Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol-O-methyltransferase are associated with familial prostate carcinoma risk in a Japanese population. Cancer, 98, 1411-6.
33. Szendroi A, Speer G, Tabak A, et al (2011). The role of vitamin D, estrogen, calcium sensing receptor genotypes and serum calcium in the pathogenesis of prostate cancer. Can J Urol, 18, 5710-6.
34. Tanaka Y, Sasaki M, Kaneuchi M, et al (2003). Polymorphisms of estrogen receptor alpha in prostate cancer. Mol Carcinog, 37, 202-8.
35. Wang J, Higuchi R, Modugno F, et al (2007). Estrogen receptor alpha haplotypes and breast cancer risk in older Caucasian women. Breast Cancer Res Treat, 106, 273-80.
36. Wedren S, Lovmar L, Humphreys K, et al (2008). Estrogen receptor alpha gene polymorphism and endometrial cancer risk-a case-control study. BMC Cancer, 8, 322.